[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.21. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
January 2, 2013

Rebooting Cancer Tissue Handling in the Sequencing EraToward Routine Use of Frozen Tumor Tissue

Author Affiliations

Author Affiliations: Scripps Genomic Medicine, Scripps Translational Science Institute (Drs Goetz and Topol), and Divisions of General Surgery (Dr Goetz), Pathology (Dr Bethel), and Cardiovascular Medicine (Dr Topol), Scripps Clinic, La Jolla, California.

JAMA. 2013;309(1):37-38. doi:10.1001/jama.2012.70832

Genomics is poised to revolutionize cancer treatment. Whole genome sequencing is becoming more rapid, accurate, and affordable, and the ability to use genomic data to match biologically based therapy to an individual is becoming a reality. As the sequencing endeavor transitions from a heroic effort performed by a dedicated team for a particular patient to a routine component of most, if not all, cancer diagnoses, standards for acquiring appropriate tissue samples also must evolve. This is necessary because an individual's native (germline) genome must be compared with the genome of the tumor.

First Page Preview View Large
First page PDF preview
First page PDF preview
×